FDA Takes Action to Halt Marketing of Unapproved Ergotamine

Armen Hareyan's picture

The Food and Drug Administration (FDA) told 20 companies to cease marketing unapproved drug products containing ergotamine tartrate. Ergotamine tartrate products are used to treat vascular headaches, including migraines. As part of the FDA's continued efforts to combat the marketing of unapproved drugs, the agency sent warning letters to eight manufacturers and 12 distributors warning them that they are subject to further enforcement action if they do not stop manufacturing and distributing these products.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.